瑞穗和巴克莱等多家投行上调联合健康目标价

Core Viewpoint - There is growing optimism in the market regarding UnitedHealth Group's performance improvement, as indicated by multiple Wall Street analysts raising their stock price targets ahead of the company's Q3 earnings report [1] Analyst Upgrades - Mizuho analyst Ann Hynes raised the target price from $300 to $430 while maintaining a "Buy" rating [1] - Barclays analyst Andrew Mok increased the target price from $352 to $386, also reaffirming a "Buy" rating [1] - Bernstein analyst Lance Wilkes raised the target price from $379 to $433 and confirmed a "Buy" rating [1] Stock Performance - Despite challenges such as high medical costs, a Department of Justice investigation, and the sudden departure of the CEO, the stock has rebounded over 7% in the past month [1] - Positive factors driving the recent recovery include Berkshire Hathaway's disclosure of its stake in the company [1] - The company reiterated its earnings guidance, and its "Medicare Advantage Plan" received favorable updates in star ratings [1]